Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: The role of hepatitis B virus (HBV) integration into the host genome in hepatocarcinogenesis following hepatitis B surface antigen (HBsAg) seroclearance remains unknown. Our study aimed to investigate and characterize HBV integration events in chronic hepatitis B (CHB) patients who developed hepatocellular carcinoma (HCC) after HBsAg seroclearance. Methods: Using probe-based HBV capturing followed by next-generation sequencing technology, HBV integration was examined in 10 samples (seven tumors and three non-tumor tissues) from seven chronic carriers who developed HCC after HBsAg loss. Genomic locations and patterns of HBV integration were investigated. Results: HBV integration was observed in six patients (85.7%) and eight (80.0%) of 10 tested samples. HBV integration breakpoints were detected in all of the non-tumor (3/3, 100%) and five of the seven (71.4%) tumor samples, with an average number of breakpoints of 4.00 and 2.43, respectively. Despite the lower total number of tumoral integration breakpoints, HBV integration sites in the tumors were more enriched within the genic area. In contrast, non-tumor tissues more often showed intergenic integration. Regarding functions of the affected genes, tumoral genes with HBV integration were mostly associated with carcinogenesis. At enrollment, patients who did not remain under regular HCC surveillance after HBsAg seroclearance had a large HCC, while those on regular surveillance had a small HCC. Conclusions: The biological functions of HBV integration are almost comparable between HBsAg-positive and HBsAgserocleared HCCs, with continuing pro-oncogenic effects of HBV integration. Thus, ongoing HCC surveillance and clinical management should continue even after HBsAg seroclearance in patients with CHB.
Abstract
Background/Aims: The role of hepatitis B virus (HBV) integration into the host genome in hepatocarcinogenesis following hepatitis B surface antigen (HBsAg) seroclearance remains unknown. Our study aimed to investigate and characterize HBV integration events in chronic hepatitis B (CHB) patients who developed hepatocellular carcinoma (HCC) after HBsAg seroclearance. Methods: Using probe-based HBV capturing followed by next-generation sequencing technology, HBV integration was examined in 10 samples (seven tumors and three non-tumor tissues) from seven chronic carriers who developed HCC after HBsAg loss. Genomic locations and patterns of HBV integration were investigated. Results: HBV integration was observed in six patients (85.7%) and eight (80.0%) of 10 tested samples. HBV integration breakpoints were detected in all of the non-tumor (3/3, 100%) and five of the seven (71.4%) tumor samples, with an average number of breakpoints of 4.00 and 2.43, respectively. Despite the lower total number of tumoral integration breakpoints, HBV integration sites in the tumors were more enriched within the genic area. In contrast, non-tumor tissues more often showed intergenic integration. Regarding functions of the affected genes, tumoral genes with HBV integration were mostly associated with carcinogenesis. At enrollment, patients who did not remain under regular HCC surveillance after HBsAg seroclearance had a large HCC, while those on regular surveillance had a small HCC. Conclusions: The biological functions of HBV integration are almost comparable between HBsAg-positive and HBsAgserocleared HCCs, with continuing pro-oncogenic effects of HBV integration. Thus, ongoing HCC surveillance and clinical management should continue even after HBsAg seroclearance in patients with CHB.
참고문헌 (18)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Bonilla Guerrero R, "The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma", J Hepatol, 42, pp.760~777 (2005)
- Budzinska MA, "Cellular genomic sites of hepatitis B virus DNA integration", Genes (Basel), 9, pp.365~ (2018)
- Wong DK, "Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis", Clin Gastroenterol Hepatol, 18, pp.449~456 (2020)
- Tamori A, "HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan", J Med Virol, 71, pp.492~498 (2003)
- Yeo YH, "Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis", Gastroenterology, 156, pp.635~646.e9 (2019)
- Summers J, "Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy", Proc Natl Acad Sci U S A, 101, pp.638~640 (2004)
- Tu T, "HBV DNA integration:molecular mechanisms and clinical implications", Viruses, 9, pp.75~ (2017)
- Pollicino T, "Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection", Gastroenterology, 126, pp.102~110 (2004)
- Jang JW, "Longterm effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)
- Li W, "HIVID: an efficient method to detect HBV integration using low coverage sequencing", Genomics, 102, pp.338~344 (2013)
- Kim BK, "HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B", Antivir Ther, 16, pp.1169~1186 (2011)
- Sung WK, "Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma", Nat Genet, 44, pp.765~769 (2012)
- Zhao LH, "Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma", Nat Commun, 7, pp.12992~ (2016)
- Pinyol R, "TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma", J Hepatol, 61, pp.685~687 (2014)
- Li X, "The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma", J Hepatol, 60, pp.975~984 (2014)
- Kim GA, "Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance", J Hepatol, 62, pp.1092~1099 (2015)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)